共被期刊论文引用了2次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Top 100 cited articles in ophthalmic epidemiology between 2006 and 2016显示文摘AIM: To identify the most-cited articles in ophthalmic epidemiology over the last decade.METHODS: We performed a cited reference search on articles that were included in the ISI Web of Science database using the terms 'Epidemi*' AND 'ophthalm*' AND 'population*' during year 2006 to 2016. TOP 100 most cited articles(T100) in ophthalmic epidemiology were short listed and analysed using bibliometrics.RESULTS: These top 100 articles in ophthalmic epidemiology were cited between 61 to 333 times. Of these T100 articles, 36% originated from United States, and 34% were published in the Ophthalmology journal. The three major topics identified were age-related macular degeneration(AMD, n=23), glaucoma(n=16) and visual impairment(n=12). The top-cited article was a study on outdoor activities and its association with the prevalence of myopia in school-aged children, published in 2008. CONCLUSION: This bibliometric analysis provides useful insights into the current development in ophthalmicepidemiology in the past decade and can help recognizing the quality of the researches, discoveries, and trends steering ophthalmic epidemiology. | Lei Liu Yan Li Gui-Sen Zhang Jing-Yang Wu Shivani Majithia Yih-Chung Tham Han Zhang Lei Chen | 2018 | International Journal of Ophthalmology(English edition)2018，11，12： | 2 |
| 2 | 基于VOSviewer的干眼热点与前沿研究显示文摘目的了解干眼相关研究热点和发展趋势,为后续研究提供参考。方法通过检索Web of Science数据库2009~2019年十年间关于干眼相关文献,采用VOSviewer聚类软件对干眼相关文献类型、作者、机构、年份等进行可视化网络分析。结果研究共纳入Web of Science数据库2009~2019年干眼相关文献7754篇,共被引用118997次,h-index为103次,发文量和被引频次每年均呈递增趋势。文献主要来源最多的期刊是'INVESTIGATIVE OPHTHALMOLOGY&VISUAL SCIENCE'。被引量排名前十的研究文献质量较高。发文量最多的国家是美国(2476,31.93%),哈佛大学是发表干眼相关文献最多的机构,TSUBOTA K在干眼相关发文量及被引频次总数都是最多的作者。通过VOSviewer软件分析共现关键词发现,关键词主要集中在基础研究、疾病、临床试验、外科手术、症状、治疗、流行病学7个族群。结论2009~2019年干眼相关文献发文量和被引频次每年均呈递增趋势。美国在干眼相关研究上较为成熟,无论在发文量和文献质量来看,都领先于其他国家。人工泪液、环孢素可能是未来治疗研究的热点,为后续干眼相关研究提供依据和参考。 | 蒋炜 胡晓莹 伍俊妍 | 2021 | 今日药学2021，31，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员